Angiotensin II (AngII) and aldosterone cooperate centrally to produce a robust sodium appetite. The intracellular signaling and circuitry that underlie this interaction remain unspecified. Male rats pretreated with both deoxycorticosterone (DOC; a synthetic precursor of aldosterone) and central AngII exhibited a marked sodium intake, as classically described. Disruption of inositol trisphosphate signaling, but not extracellular-regulated receptor kinase 1 and 2 signaling, prevented the cooperativity of DOC and AngII on sodium intake. The pattern of expression of the immediate early gene product cFos was used to identify key brain regions that may underlie this behavior. In the paraventricular nuclei (PVN) of the hypothalamus, DOC pretreatment diminished both AngII-induced cFos induction and neurosecretion of oxytocin, a peptide expressed in the PVN. Conversely, in the organum vasculosum lateral terminalis (OVLT), DOC pretreatment augmented cFos expression. Immunohistochemistry identified a substantial presence of oxytocin fibers in the OVLT. In addition, when action potentials in the PVN were inhibited with intraparenchymal lidocaine, AngII-induced sodium ingestion was exaggerated. Intriguingly, this treatment also increased the number of neurons in the OVLT expressing AngII-induced cFos. Collectively, these results suggest that the behavioral cooperativity between DOC and AngII involves the alleviation of an inhibitory oxytocin signal, possibly relayed directly from the PVN to the OVLT.
Introduction
The hormones angiotensin (AngII) and aldosterone are key defenders of electrolyte balance, blood volume, and blood pressure (Peach, 1977) . In the event of sodium depletion, hypovolemia, and/or hypotension, AngII and aldosterone are produced, which engage homeostatic responses, including a prodigious drive for sodium consumption (Ganong, 1977) . Exogenous administration of either hormone alone produces a modest sodium intake; however, combined treatments result in markedly greater sodium consumption (Fluharty and Epstein, 1983) , suggesting cooperative neural mechanisms. Steady progress has been made in revealing the independent natriorexic effects of AngII and aldosterone; however, the mechanism for the cooperative actions of AngII and aldosterone to promote a greater than additive effect on sodium ingestion remains unclear.
An intriguing model has been proposed to explain the synergistic actions of AngII and aldosterone on sodium ingestion based on disinhibition (Stricker and Verbalis, 1987; Blackburn et al., 1992a) . In particular, central AngII activates oxytocin neurons in the paraventricular nuclei (PVN) and supraoptic nuclei (SON; Akaishi et al., 1980) . Given that centrally released oxytocin suppresses sodium ingestion, AngII would be expected to elicit limited salt intake. Pretreatment with a mineralocorticoid diminishes AngII-induced oxytocin neuronal activation (Stricker and Verbalis, 1996, 2004; Roesch et al., 2001) , thereby disinhibiting natriorexia. The exact role of oxytocin in the aldosterone-AngII interaction on sodium appetite remains unclear (Blackburn et al., 1992a; Fitts et al., 2003; Rigatto et al., 2003) . In particular, the brain region in which oxytocin acts to inhibit sodium appetite is unknown.
A variety of studies have provided insight into the behavioral and endocrine effects of AngII. Circulating AngII binds to AngII type 1 receptors (AT1R) in the subfornical organ (SFO) and organum vasculosum lateral terminalis (OVLT), brain regions with an incomplete blood-brain barrier (Ganong, 1984) . The SFO and OVLT relay information to the PVN and SON (Miselis, 1981; McKinley et al., 1992b) to prompt secretion of arginine vasopressin (AVP) and oxytocin (Bisset et al., 1971 ). The AT1R is a heptahelical receptor that triggers inositol 1,4,5-triphosphate (IP3) production and Ca 2ϩ mobilization (Smith et al., 1984; Enjalbert et al., 1986; Taylor et al., 1990; Beresford and Fitzsimons, 1992) . In parallel, mitogen-activated protein kinase kinase (MEK) becomes phosphorylated, which activates the p42 and p44 isoforms of mitogen-activated protein kinase, also referred to as extracellular signal-regulated kinase 1 and 2 (ERK1/2; Sadoshima et al., 1995) . IP3 signaling mediates AngII-induced thirst, whereas the ERK1/2 signaling pathway mediates sodium appetite (Daniels et al., 2005 (Daniels et al., , 2009 Felgendreger et al., 2013) . It is unclear whether these AngII-induced signal transduction pathways are affected by mineralocorticoids in brain targets.
To investigate the model of Aldo-AngII-oxytocin control of sodium appetite, we took a multidisciplinary approach investigating signal transduction, functional neuroanatomy, and reversible lesions. Initial results were inconsistent with the view that mineralocorticoids simply amplify the signaling effects of AngII. Subsequent findings implicated an inhibitory oxytocinergic link between the PVN and the OVLT. Together, these results confirm and extend the working model that the aldosterone-AngII cooperative effect on sodium appetite involves hypothalamic disinhibition.
Materials and Methods
Animals. Adult male Sprague-Dawley rats (n ϭ 68) that weighed between 225 and 250 g were obtained from Charles River Laboratories. Rats were housed in groups of two in plastic tubs with standard bedding and with food and water available ad libitum, except during experimental procedures. The temperature in the colony was maintained at 22°C with a 12 h reversed light/dark cycle. Animals were allowed at least 1 week to acclimate to the colony before any procedures were performed. The Institutional Animal Care and Use Committee of the University of Pennsylvania approved all procedures with animals.
Drugs. Deoxycorticosterone acetate (DOC; Sigma-Aldrich) was administered subcutaneously (s.c.) at a dose of 0.25 mg in 0.2 ml of sesame oil (Sigma-Aldrich). DOC is typically used instead of aldosterone because it penetrates the blood brain barrier more easily than aldosterone because of its low capacity for hydrogen bond formation (Geerling and Loewy, 2009) . Sesame oil was administered at 0.2 ml subcutaneously as a control. The specific doses for each drug given intracerebroventricularly were as follows: 2.0 or 20.0 ng AngII in a volume of 2.0 l (Bachem), 2.0 nmol U0126 dissolved in 10% DMSO in a volume of 2.0 l (Promega), 20.0 ng xestospongin-C (XC) dissolved in 2% DMSO in a volume of 2.0 l (Tocris Bioscience), 8.5 nmol/side of 2% lidocaine in a volume of 0.4 l (Phoenix Pharmaceuticals), 10.0 g oxytocin in a volume of 1 l (Bachem; catalog # H-2510). Artificial CSF (aCSF; R&D Systems) plus 10% DMSO was administered intracerebroventricularly as a vehicle control in a volume of 2.0 l.
Surgeries. Surgeries were performed in aseptic conditions. Animals were anesthetized with isofluorane gas before being fixed in a stereotaxic frame and implanted with a 26 gauge guide cannulae (Plastics One) aimed at the lateral ventricle. For the lateral ventricle surgeries, coordinates were as follows: 0.48 mm caudal to bregma, 1.6 mm from mid-line and 4.2 mm ventral to dura mater. For the lidocaine experiments, an additional 26 gauge double-guide cannula (0.8 mm apart) was implanted into the PVN. For PVN double cannulae, coordinates were as follows: 1.8 mm caudal to bregma, 0.4 mm from the mid-line, and 7.7 mm ventral to dura mater. These coordinates were chosen to allow an internal injection cannula to extend beyond the guide cannula into either the ventricular space or the PVN itself. The cannulae were fixed in place with dental cement and bone screws, and the animals were allowed at least 5d to recover before verification procedures were performed. After surgery, animals were injected with yohimbine (0.11 mg/kg, Ben Venue Laboratories). Upon awakening, animals were singly housed.
Five days after surgery and before undergoing experimental treatments, animals were tested for correct lateral ventricle cannula placement and patency. They were given an intracerebroventricular injection of 20.0 ng of AngII diluted in aCSF via a Hamilton syringe connected with PE-10 tubing to an injector that terminated 1 mm beyond the guide cannula. Animals were excluded from the experiment if they failed to demonstrate a drinking response in Ͻ30 s consuming at least 3 ml of water in two separate AngII challenges. Animals began behavioral testing 3 d after the intracerebroventricular test injections.
Behavioral studies. Rats were placed in individual wire mesh-bottomed cages with water and food available ad libitum. One day before injections, rats acclimated for 1 h to two 25 ml bottles containing tap water and 1.5% saline, each marked with 0.2 ml graduations. Vehicle or DOC (0.25 mg) was administered to each rat in 0.2 ml of sesame oil twice daily (10 h apart) for 3 d.
To investigate the role of ERK1/2 in this model of water and sodium consumption, rats were assigned to specific intracerebroventricularly conditions on the fourth day: vehicle, U0126, AngII, or U0126 plus AngII. U0126 was administered 15 min before AngII in the last condition (Daniels et al., 2009; Felgendreger et al., 2013) . To examine the role of the OVLT activation in the potentiation of sodium appetite, rats were assigned to specific intracerebroventricular conditions on the fourth day: vehicle, XC, AngII, or XC plus AngII. XC was administered 20 min before AngII in the last condition (Brennan et al., 2008; Li et al., 2011) . To evaluate the role of the PVN in DOC and AngII-induced sodium appetite, rats were administered either vehicle or lidocaine directly into the PVN over the course of 1 min, followed 5 min later by injection of vehicle or AngII intracerebroventricularly Fernandes et al., 2007) . The bilateral lidocaine injection was performed using a dual infusion pump (Harvard Apparatus). In an additional study examining the role of oxytocin in sodium appetite, oxytocin or vehicle was administered intracerebroventricularly15 min before injections of lidocaine and AngII (Blackburn et al., 1992b) .
For all behavioral experiments, after the last drug treatment was given, rats were returned to their cages, and water and saline levels were measured at 15 min intervals for the first hour and then at 30 min intervals for the next hour. Food was not available during behavioral testing.
Western blot. Animals were pretreated twice daily for 3 d (10 h apart) with vehicle or DOC, as described above. On day 4, rats were administered either vehicle, 2 ng AngII, or 20 ng AngII intracerebroventricularly. Two minutes after the last injections, animals were rapidly decapitated and brains were flash frozen in hexane over dry ice. Using a cryostat, 1 mm punches of brain regions of interest (OVLT, SFO, PVN, SON) were collected from 300 m slices. The OVLT and SFO were combined and the PVN and SON punches were combined from each rat to ensure sufficient tissue. Punches were immersed in lysis buffer containing 25 mM Tris-HCl, pH 8, protease inhibitors (pepstatin, leupeptin, aprotinin), and phosphatase inhibitors (sodium pyrophosphate, sodium fluoride, sodium molybdate, phenylarsin oxide, and sodium orthovanadate). The OVLT/SFO and PVN/SON punches were immersed in 50 and 100 l of lysis buffer, respectively. Brain punches were sonicated for 3 s followed by centrifugation at 14,000 rpm in 4°C for 15 min. Supernatant was collected and a bicinchoninic acid (BCA) protein assay was performed on 5 l of each sample. Based on the protein levels detected by BCA, appropriate amounts of sample and sample buffer were loaded into wells of a SDS polyacrylamide gel. Western blot for phospho-and total-ERK1/2 was performed using the LiCor Odyssey System. The following antibodies were used: phospho-ERK1/2 (Thr202/Tyr204; E10) Mouse mAb no. 9106 (Cell Signaling Technology); Erk 1 Antibody (C-16): sc-93 (Santa Cruz Biotechnology); IRDye 800CW Goat anti-Mouse IgG (H ϩ L; Li-Cor Biosciences); IRDye 680LT Goat anti-Rabbit IgG (H ϩ L; LiCor Biosciences).
Immunohistochemistry. To observe brain activation after DOC and AngII treatments, rats were pretreated twice daily for 3 d (10 h apart) with vehicle or DOC. On day 4, rats were administered either vehicle or 20 ng AngII intracerebroventricularly. To determine the efficacy of XC in blocking calcium release, rats were injected intracerebroventricularly with vehicle, XC, AngII, or XC plus AngII. To examine the effect PVN inactivation on cFos expression in other brain areas, rats were injected with either: lidocaine or vehicle in the PVN, followed 5 min later by either: vehicle or 20 ng AngII intracerebroventricularly. Sixty minutes after the last intracerebroventricular injection in each study, each rat was anesthetized with 50 mg/kg ketamine and 20 mg/kg xylazine, intraperitoneally (i.p.). They were perfused transcardially with 100 ml of heparinized saline followed by 200 ml 4% paraformaldehyde (Electron Microscopy Sciences). The brains were isolated, postfixed in paraformaldehyde overnight at 4°C, then submerged in 20% sucrose in 0.1 M phosphate buffer for 3 d. Coronal sections were cut on a freezing microtome into three serial sets of 40-m-thick sections. These slices encompassed the OVLT, SFO, PVN, and SON. One set from each animal underwent immunohistochemical staining and analysis. Rostral-caudal coordinates (relative to bregma) for each brain region analyzed are as follows: OVLT ϭ ϩ0.60 mm to ϩ0.12 mm; SFO ϭ Ϫ0.60 mm to Ϫ1.44 mm; PVN ϭ Ϫ1.56 mm to Ϫ1.92 mm; SON ϭ Ϫ0.48 mm to Ϫ1.32 mm. These correspond to specific figures in the rat brain atlas (Paxinos and Watson, 1986 (Oldfield et al., 1994; Bisley et al., 1996) . Sections were matched to these atlas coordinates, with four to six sections total per brain region within each animal and six animals per treatment group.
For cFos immunohistochemistry, sections were washed in Trisbuffered saline (TBS), pH 7.4, then incubated with a cFos antibody (1: 500, sc-52, rabbit; Santa Cruz Biotechnology) in TBS with 0.2% Triton X-100 and 3% normal donkey serum (Jackson Immunoresearch) overnight at 4°C. After several washes, sections were incubated with a biotin-SP-conjugated AffiniPure donkey anti-rabbit IgG (1:100, Jackson Immunoresearch) in TBS with 0.2% Triton X-100 and 3% normal donkey serum for 2 h at room temperature. After several washes, sections were incubated with the Vectastain ABC kit (Vector Laboratories) for 1 h. This was followed by another set of washes before staining with 3Ј3Ј-diaminobenzidine (Sigma-Aldrich) for 10 min. After a final set of washes, sections were mounted on slides, air-dried, and coverslipped with DPX mounting media (Electron Microscopy Sciences).
A subset of sections including the OVLT was double-labeled for AngIIinduced cFos and oxytocin immunohistochemistry. Immunohistochemistry was performed as previously described, except with another cFos primary antibody (1:500, sc-8047, mouse, Santa Cruz Biotechnology) and an oxytocin antibody (1:500, T-4084, rabbit; Bachem). The specificity of cFos has been previously reported (Hebert et al., 2005) . The oxytocin antibody was raised against the nonapeptide oxytocin (H-CysTyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH 2 ). Radioimmunoassay data provided by the manufacturer reported 100% and 0% cross-reactivity for oxytocin and vasopressin, respectively. We performed additional specificity tests previously (Griffin et al., 2010) , including omission of the primary or secondary antisera, preabsorption with the oxytocin peptide, and the lack of labeling in oxytocin knock-out mice, unlike the sections from wild-type littermates stained in parallel. The lack of cross-reactivity between the labeling of each primary antiserum was verified by the cellular compartmental specificity of cFos versus oxytocin labeling when each was labeled individually: cFos was never observed in fibers, and oxytocin was never localized to the nucleus. The secondary antibodies used for this staining were biotin-SP-conjugated AffiniPure donkey antimouse IgG and donkey-antirabbit IgG (1:100, Jackson Immunoresearch).
Images were acquired with a digital camera (Diagnostic Instruments, model RTKE), maintaining the same microscope and camera settings to ensure the same level of light and exposure for all images. Background was subtracted from images using Photoshop, and images were thresholded to the same level (200). Images were further analyzed in NIH ImageJ using standardized boxes for each brain region (calculated using the rat brain atlas; Paxinos and Watson, 1986) , using the analyze particles function. Pixel size minimum was 15 and circularity was set to 0.35. All image analysis was performed with the experimenter blind to the treatment groups.
Oxytocin secretion. Animals were pretreated twice daily for 3 d with vehicle or DOC, as described previously. On day 4, rats were administered either vehicle or 20 ng AngII intracerebroventricularly. Two minutes after the last injections, animals were rapidly decapitated and trunk blood was collected into 10 ml BD Vacutainer blood collection heparinized glass tubes on ice. The tubes then were centrifuged at 4°C at 1300 relative centrifugal force for 10 min. The plasma supernatant was extracted with acetone and petroleum ether. Plasma levels of oxytocin and AVP were measured with a specific radioimmunoassay performed by the laboratory of Dr Joseph G. Verbalis, as described previously (Verbalis et al., 1986) . The standard curve for each peptide was linear between 0.25 and 5 U per tube with the oxytocin standard and between 0.5 and 10.0 pg per tube using a synthetic AVP (Bachem Americas). The minimum detectable concentration of oxytocin or AVP in extracted plasma was 0.25 U/ml and 0.5 pg/ml, respectively. The oxytocin antiserum exhibited Ͻ1% cross-reactivity with AVP, and the AVP antiserum (R-4) displayed Ͻ1% cross-reactivity with oxytocin.
Statistical analysis. Data are presented as the mean Ϯ SEM. For all experiments, comparisons were made between treatment groups (with either a one-way, two-way, or three-way ANOVA). When warranted, planned comparison post hoc t tests were performed. All hypothesis tests used ␣ ϭ 0.05 as the criterion level of significance. Statistical analyses were conducted using Prism 2.0 software for one-way or two-way ANOVAs and Statistica 12 Ultimate Academic Bundle for three-way ANOVAs.
Results
The role of ERK1/2 in DOC and AngII-induced sodium appetite Consistent with previous research (Fluharty and Epstein, 1983) , DOC pretreatment potentiated AngII-induced sodium intake, but not water intake (Fig. 1A) . A two-way ANOVA established a main effect for both AngII (F (2,54) ϭ 10.7, p Ͻ 0.001) and DOC (F (1,54) ϭ 29.6, p Ͻ 0.001) on sodium intake, as well as an interaction between the two treatments (F (2,54) ϭ 3.2, p ϭ 0.046; n ϭ 12 rats/treatment group). Bonferonni post hoc t tests revealed a significant difference between each dose of AngII and the respective DOC pretreated condition ( p Ͻ 0.001 for the 2 ng AngII dose; p ϭ 0.020 for the 20 ng AngII dose). Regarding water intake, a two-way ANOVA supported a main effect for AngII (F (2,60) ϭ 31.1, p Ͻ 0.001), but not DOC (F (1,60) ϭ 0.7, p ϭ 0.400), to increase water intake.
The role of ERK1/2 in the interaction between AngII and DOC to induce sodium appetite was investigated by using the MEK inhibitor U0126 (Fig. 1B) . A three-way ANOVA indicated that there was no interaction between all three variables on sodium intake (F (1,153) ϭ 1.5, p ϭ 0.222). However, there was an interaction between DOC and AngII (F (1,153) ϭ 8.1, p ϭ 0.001), as reported in Figure 1A . Additionally, there was an interaction between the MEK inhibitor and AngII (F (1,153) ϭ 3.1, p ϭ 0.050). Specifically, U0126 significantly reduced sodium intake induced by 20 ng AngII alone (6.6 Ϯ 1.8 vs 2.2 Ϯ 1.0 ml, p ϭ 0.003; planned comparison t tests; n ϭ 18 rats/treatment group), as shown previously (Daniels et al., 2009; Felgendreger et al., 2013) . However, the MEK inhibitor U0126 did not reduce sodium intake elicited by combined DOC and AngII treatments; in the 2 ng AngII condition, U0126 enhanced DOC/AngII induced sodium appetite (5.1 Ϯ 0.9 vs 8.5 Ϯ 0.8 ml, p ϭ 0.010, for the 2.0 ng dose of AngII; 11.3 Ϯ 1.4 vs 12.6 Ϯ 2.3 ml, p ϭ 0.270, for the 20 ng dose of AngII). U0126 did not diminish the effect of AngII on water consumption.
The effect of these hormonal treatments on the activation of ERK1/2 in OVLT, SFO, PVN, and SON then was measured by Western blot analysis, as shown in Figure 1C . A two-way ANOVA supported a main effect of AngII alone, but not DOC alone, on ERK1/2 phosphorylation (F (2, 20) (2, 20) ϭ 3.9, p ϭ 0.035), such that in the presence of DOC, AngII treatment no longer activated ERK1/2. In short, these results did not support the hypothesis that DOC potentiated the effects of central AngII on sodium appetite by further increasing phospho-ERK1/2 levels in relevant brain regions. Nevertheless, the negative interaction between DOC and AngII on ERK1/2 activation in circumventricular and neuroendocrine regions suggested that further investigation of these areas was warranted.
The interaction of DOC and AngII on cFos activation in the brain
To further explore the neurological mechanisms that underlie the behavioral cooperativity of DOC and AngII, cFos immunohistochemistry was used to detect a unique pattern of brain activity Figure 1 . Erk1/2 is not necessary for the DOC/AngII potentiation of sodium appetite. A, Bar graphs illustrating the potentiation of AngII-induced sodium but not water intake by DOC (n ϭ 12/group). B, Bar graphs illustrating the effect of blocking ERK1/2 activation on DOC and AngII-induced sodium and water intake (n ϭ 18/group). DOC potentiated 2 and 20 ng AngII-induced sodium intake. This behavior was not reduced by the MEK inhibitor U0126; however, U0126 reduced sodium intake with 20 ng AngII alone. AngII-induced water intake was not potentiated by DOC. C, Bar graphs illustrating phosphorylated ERK1/2 levels in the OVLT/SFO and PVN/SON after either oil or DOC pretreatment followed by intracerebroventricular treatments with 2 or 20 ng AngII (n ϭ 6/group). AngII treatment induced significant ERK1/2 phosphorylation compared with vehicle in both sets of brain regions. DOC pretreatment did not enhance this activation. Representative Western blot images of ERK1/2 phosphorylation are shown above each quantified bar. For the sake of clarity, only specific statistical differences are highlighted. "A" indicates AngII is different from vehicle; "B" indicates DOC/AngII is different from AngII; "C" indicates U0126/AngII is different from AngII; and "D" indicates U0126/DOC/AngII is different from DOC/AngII, p Ͻ 0.05. Veh, Vehicle.
that might correspond to the behavioral effects of these hormones. As illustrated in Figure 2A , brain sections from OVLT, SFO, PVN, and SON were analyzed for cFos immunolabeling. In the OVLT, a two-way ANOVA revealed a main effect for both AngII and DOC on cFos expression (F (1,17) ϭ 16.4, p Ͻ 0.001; F (1,17) ϭ 12.8, p ϭ 0.002; n ϭ 6 rats/treatment group, 4 -6 sections per brain area). Bonferonni post hoc tests indicated that cFos levels were significantly enhanced compared with vehicle for all treatment groups (vehicle: 8.7 Ϯ 1.9, DOC: 30.2 Ϯ 6.3, AngII:
32.7 Ϯ 4.4, DOC and AngII: 49.3 Ϯ 6.0; p ϭ 0.021, p ϭ 0.003, p Ͻ 0.001). In the SFO, a two-way ANOVA indicated a main effect for AngII on cFos expression (F (1,16) ϭ 32.5, p Ͻ 0.001). Bonferonni post hoc tests noted that cFos levels were similar for vehicle and DOC, but both AngII and DOC/AngII treatments significantly enhanced staining (vehicle: 11.5 Ϯ 2.6, DOC: 22.1 Ϯ 6.0, AngII: 56.8 Ϯ 5.9, DOC and AngII: 47.4 Ϯ 7.6; p ϭ 0.200, p ϭ 0.001, p ϭ 0.004). In the PVN, a two-way ANOVA revealed a main effect for AngII, DOC, and an interaction between the two variables on Figure 2 . DOC pretreatment enhanced AngII-induced OVLT activation and reduced PVN activity and oxytocin (OT) release. A, Bar graphs illustrating cFos cell counts in different brain areas (OVLT, SFO, PVN, and SON) after either vehicle or DOC pretreatment followed by intracerebroventricular vehicle or 20 ng AngII (n ϭ 6/group). In the OVLT, each treatment condition induces cFos immunostaining compared with vehicle; DOC/AngII induced additional cFos immunostaining. In the SFO, both AngII alone and DOC/AngII induced more cFos staining than either vehicle or DOC alone. cFos labeling in the PVN was increased by AngII, but DOC reduced the AngII-induced cFos expression to control levels. In the SON, AngII induced cFos staining. Representative images of the OVLT and PVN (coronal plane, 10ϫ) in each treatment condition are shown above the bar graphs. Representative images of SFO and SON are not shown, but similar data were seen. B, Bar graphs illustrating oxytocin and AVP plasma levels after either vehicle or DOC pretreatment followed by intracerebroventricular vehicle or 20 ng AngII (n ϭ 8/group). AngII treatment increased oxytocin levels, and this effect was reduced by DOC pretreatment. However, AngII treatment elevated AVP levels, regardless of pretreatment. For the sake of clarity, only specific statistical differences are highlighted. "A" indicates AngII is different from vehicle; "B" indicates DOC/AngII is different from AngII. Veh, Vehicle.
cFos expression (F (1,18) ϭ 16.4, p Ͻ 0.001; F (1,18) ϭ 7.5, p ϭ 0.014, F (1,18) ϭ 7.0, p ϭ 0.016). Bonferonni post hoc tests indicated that AngII significantly increased cFos staining compared with vehicle in the PVN (126.3 Ϯ 5.3 vs 59.4 Ϯ 6.9, p Ͻ 0.001), and DOC reduced AngII-induced cFos staining to vehicle levels (126.3 Ϯ 5.3 vs 72.5 Ϯ 14.4, p ϭ 0.006). In the SON, a two-way ANOVA revealed a main effect for AngII on cFos expression (F (1,16) ϭ 7.9, p ϭ 0.013). Post hoc tests indicated that AngII induced a significant amount of cFos staining compared with vehicle (40.4 Ϯ 6.6 vs 14.6 Ϯ 3.7, p ϭ 0.020). There was a trend for DOC to reduce AngII-induced Fos staining compared with AngII alone (25.4 Ϯ 5.0 vs 40.4 Ϯ 6.6, p ϭ 0.100). In short, the most striking interactions between DOC and AngII on cFos labeling were the enhanced cFos staining in the OVLT and the suppressed cFos levels in the PVN.
The observation that DOC diminished the AngII-induced Fos activation in the PVN is reminiscent of previous studies that demonstrated that DOC inhibits oxytocin neuron activity in the PVN, thereby disinhibiting sodium intake (Roesch et al., 2001) . We tested whether the DOC treatment was associated with alterations in AngII-induced neurohypophysial secretion. Plasma levels of oxytocin and AVP were measured by radioimmunoassay after DOC, AngII, or both hormone treatments, 2 min after the AngII treatment (Fig. 2B) . A two-way ANOVA revealed a main effect for both AngII and DOC, as well as an interaction between the two hormones on oxytocin secretion (F (1,27) ϭ 4.2, p ϭ 0.049; F (1,27) ϭ 4.4, p ϭ 0.045; F (1,27) ϭ 5.7, p ϭ 0.020, n ϭ 8 rats/ treatment group). AngII increased oxytocin levels significantly compared with vehicle (12.8 Ϯ 2.9 vs 6.4 Ϯ 0.8 pg/ml, p ϭ 0.048). DOC reduced these AngII-induced oxytocin levels back down to control levels (12.8 Ϯ 2.9 vs 5.1 Ϯ 1.2 pg/ml, p ϭ 0.035). In contrast, there was no effect of DOC on AngII-induced AVP secretion.
Together, these results demonstrate parallel changes in cFos expression in the OVLT, PVN oxytocin activity, and the natriorexic effect of combined DOC and AngII. We next sought to determine whether disruption of cFos induction in the OVLT with an IP3 receptor antagonist would impair the behavioral cooperativity of DOC and AngII.
The role of IP3 in DOC and AngII-induced sodium appetite IP3 signaling was blocked with an antagonist to the IP3 receptor, namely XC. First the bioactivity of centrally administered XC was verified by assaying AngII-induced cFos immunohistochemistry in Figure 3A . Given that cFos is an immediate early gene activated by IP3-induced intracellular calcium signaling, an effective IP3 receptor antagonist should prevent calcium signaling, and thereby cFos expression (Clark et al., 1992; Templeton et al., 1998; Jomphe et al., 2003; Daniels et al., 2005; Zhang et al., 2012) . A two-way ANOVA indicated main effects of AngII and XC, and an interaction on cFos expression (F (1,17) ϭ 6.0, p ϭ 0.026; F (1,17) ϭ 6.0, p ϭ 0.026; F (1,17) ϭ 5.7, p ϭ 0.029; respectively) in the OVLT (n ϭ 6 rats/treatment group, 4 -6 sections per brain area). In particular, Bonferroni post hoc tests suggest that XC pretreatment significantly reduced the number of AngII-induced cFoslabeled neurons (35.8 Ϯ 5.2 vs 11.7 Ϯ 1.6, p ϭ 0.002). Labeling in the SFO exhibited a main effect for AngII, but not XC (F (1,15) ϭ 7.2, p ϭ 0.020; F (1,15) ϭ 0.9, p ϭ 0.360). However, there was a significant interaction between AngII and XC (F (1, 15) Having demonstrated that the XC treatment effectively blocked IP3-induced cFos in relevant brain regions, the role of IP3 in AngII and DOC induced sodium appetite was investigated (Fig. 3B) . A three-way ANOVA indicated that sodium intake differed between treatment groups (F (1,68) ϭ 6.5, p ϭ 0.010; n ϭ 10 rats/treatment group). Consistent with Figure 1 , DOC enhanced AngII-induced sodium intake ( p ϭ 0.006). XC did not affect sodium ingestion in animals treated with AngII alone (8.3 Ϯ 1.8 vs 8.3 Ϯ 1.7 ml, p ϭ 0.990). However, XC reduced the DOC and AngII enhancement of sodium intake to levels similar to the AngII alone group (15.1 Ϯ 1.3 vs 10.9 Ϯ 1.3 ml, p ϭ 0.030). Likewise, a three-way ANOVA revealed that water intake differed between treatment groups (F (1,51) ϭ 5.8, p ϭ 0.020). Post hoc tests indicated that XC reduced AngII-induced water intake (11.0 Ϯ 1.6 vs 6.9 Ϯ 1.0 ml, p ϭ 0.030). However, when both DOC and AngII were present, XC did not reduce water intake (8.7 Ϯ 1.1 vs 9.2 Ϯ 1.8 ml, p ϭ 0.810). Together, these results suggest that IP3 signaling, possibly in the OVLT, is necessary for the cooperative actions of DOCA and AngII on sodium appetite. Previous work suggested that DOC enhances AngII-induced sodium appetite via the suppression of oxytocin activity in the PVN (Stricker and Verbalis, 1987; Blackburn et al., 1992a) , and several findings reported here are consistent with that hypothesis. Therefore, the next experiment was designed to manipulate PVN activity and measure the effect on sodium appetite and neuronal activation in the OVLT.
Sodium appetite and OVLT activation after suppression of PVN activity
Neural activity in the PVN was suppressed with bilateral injections of lidocaine above the PVN. Behavioral analysis included only animals with cannula tract locations verified to be above the PVN (Fig. 4A ). Animals were treated with either vehicle or lidocaine into the PVN, followed by either vehicle or AngII (20 ng, i.c.v.) . A two-way ANOVA revealed a main effect for AngII and lidocaine, as well as an interaction on sodium intake (F (1, 20) ϭ 21.5, p ϭ 0.001; F (1,20) ϭ 5.2, p ϭ 0.035; F (1,20) ϭ 6.7, p ϭ 0.020; n ϭ 10 rats/treatment group). As shown in Figure 4B , AngII increased sodium intake compared with vehicle (5.6 Ϯ 1.0 vs 2.0 Ϯ 0.6 ml, p ϭ 0.040). Additionally, lidocaine enhanced AngIIinduced sodium intake significantly (9.5 Ϯ 1.2 vs 5.5 Ϯ 1.4 ml p ϭ 0.045). Conversely, a two-way ANOVA revealed a main effect for AngII but not lidocaine on water intake (F (1,23) ϭ 28.8, p Ͻ 0.0001; F (1,23) ϭ 0.1, p ϭ 0.740). Post hoc tests denoted AngII plus or minus lidocaine-treated rats drank very similar amounts of water (9.1 Ϯ 1.5 vs 8.6 Ϯ 1.0 ml, p ϭ 0.760), but both groups drank significantly more than vehicle-treated rats (0.5 Ϯ 0.5 ml, p ϭ 0.02 and p ϭ 0.009). A subset of rats was treated with oxytocin (10.0 g, i.c.v.) in the lidocaine plus AngII condition. Oxytocin coadministration decreased sodium intake to vehicle levels (9.5 Ϯ 1.2 vs 2.1 Ϯ 0.7 ml, p ϭ 0.001). However, oxytocin treatment also partially decreased water intake in the lidocaine plus AngII group (8.6 Ϯ 1.0 vs 4.7 Ϯ 1.2 ml, p ϭ 0.030). In summary, lidocaine in the PVN enhanced AngII-induced sodium intake, but not water intake, mimicking the effects of DOC pretreatment.
After the behavioral studies, AngII-induced cFos immunohistochemistry was performed on the brains of these animals to verify the efficacy of lidocaine administration to the PVN and to test the hypothesis that PVN activity may restrain sodium appetite by inhibiting neural activity in the OVLT (Fig. 4C) . Based on the behavioral results, these treatments were selected for comparison: vehicle/vehicle; vehicle/AngII; and lidocaine/AngII. Oneway ANOVA indicated that cFos expression in the OVLT differed between treatment groups (F (2,21) ϭ 34.47, p Ͻ 0.001; n ϭ 6 rats/treatment group, 4 -6 sections per brain area). Post hoc tests indicated that lidocaine further enhanced 20 ng AngII-induced cFos expression in the OVLT (33.29 Ϯ 3.0 vs 54.60 Ϯ 3.0, p ϭ 0.001), emulating the effects seen with DOC pretreatment. Additionally, cFos expression in the PVN was reduced with lidocaine pretreatment, illustrating reduced PVN activity (140.6 Ϯ 15.6 vs 88.5 Ϯ 3.5, p ϭ 0.010).
The previous experiments implicate the OVLT in the control of sodium appetite, in possible relation with centrally released oxytocin, a key inhibitor of sodium appetite. Although oxytocin receptor mRNA has been described in the OVLT (Yoshimura et al., 1993) , the physiological delivery of oxytocin to the OVLT remains unclear. As shown in Figure 5 , varicose oxytocinimmunoreactive fibers are present in the OVLT. In particular, the oxytocinergic fibers are abundant in the dorsal cap of the OVLT in close association with neurons expressing AngII-induced cFos.
Discussion
Classic studies showed that AngII and adrenal steroids work cooperatively to elicit a robust salt appetite when elevated concurrently, as occurs during hypovolemia and sodium depletion (Stricker and Wolf, 1966; Stricker, 1966 Stricker, , 1971 Epstein, 1982; Toth et al., 1987) . This potentiation of sodium appetite has been observed in various species and is not secondary to natriuresis (Fluharty and Epstein, 1983; Massi and Epstein, 1990; Shade et al., 2002) . Experiments with agonists and antagonists confirmed the validity of the "synergy hypothesis" in situations in which the appetite was associated with elevated endogenous levels of AngII and aldosterone (Sakai et al., 1986) . The present report initially tested the hypothesis that DOC and AngII actions converge on the ERK1/2 signaling pathway, given that adrenal steroids can Representative images of the SFO are not shown, but similar data were seen. AngII induced cFos staining in both the OVLT and SFO, and the effect was reduced by XC. B, Bar graphs illustrating the effect of XC on DOC and 20 ng AngII induced sodium and water intake (n ϭ 10/group). DOC potentiates AngII-induced sodium intake; this effect was impaired by the IP3 receptor inhibitor XC. XC did not affect sodium intake induced by AngII alone. AngII-induced water intake was reduced by XC. For the sake of clarity, only specific statistical differences are highlighted. "A" indicates AngII is different from vehicle; "B" indicates DOC/AngII is different from AngII; "C" indicates XC/AngII is different from AngII; "D" indicates XC/DOC/AngII is different from DOC/AngII; p Ͻ 0.05. Veh, vehicle. increase AT1R expression (Ullian et al., 1992; Harada et al., 2001; Mazak et al., 2004) and enhance their cellular signaling (Lemarié et al., 2008 (Lemarié et al., , 2009 ). However, behavioral and biochemical studies did not support this hypothesis. Rather, IP3 signaling, which did not mediate the sodium appetite induced by either hormone alone, was necessary for the behavioral cooperation. Functional neuroanatomy analysis revealed that the combined DOC and AngII treatment suppressed cFos activation in the PVN, reduced neurosecretion of oxytocin, and augmented cFos expression in the OVLT. This led to the novel hypothesis that DOC-induced suppression of oxytocin neural activity in the PVN relieves inhibition in the OVLT to allow a robust sodium ingestion. Local lidocaine administration into the PVN, which prevented AngII-induced cFos expression in the PVN, concomitantly elevated sodium appetite and cFos activation in the OVLT. Finally, immunohistochemical analysis demonstrated that the OVLT is well supplied with oytocin fibers, especially in the vicinity of AngII-induced cFos expression. Thus, the present studies provide further support for an inhibitory signal arising from the oxytocin neurons in PVN and provide novel evidence that oxytocin may act in the OVLT.
Lack of support for an amplification of ERK1/2 signaling
Central AngII administration activates ERK1/2 in the SFO and PVN (Wei et al., 2009) , and ERK1/2 signaling is specifically required for the sodium appetite that emerges after exogenous AngII treatment (Daniels et al., 2005) and endogenous AngII production (Felgendreger et al., 2013) . Thus, we hypothesized that ERK1/2 also would be critical for the cooperative effect of DOC and AngII on sodium intake. Behavioral pharmacology and signaling biochemistry experiments, although replicating the previous finding of AngII-induced ERK1/2 and ERK1/2-dependent sodium appetite, did not support a role for ERK1/2 in the combined effect of DOC and AngII. One interpretation of this result is that DOC removes both excitatory and inhibitory effects of AngII. On the contrary, DOC enhances AngIIinduced cFos expression in the OVLT, suggesting that at least some excitatory effects of AngII remain and may contribute to the behavioral synergy.
The interaction of DOC and AngII on IP3-mediated cFos induction
The AT1R is coupled with intracellular IP3 formation (Smith et al., 1984; Enjalbert et al., 1986; Taylor et al., 1990; Beresford and Fitzsimons, 1992) , which in turn acts on the IP3 receptor on the endoplasmic reticulum to liberate intracellular calcium as a third messenger (Nabika et al., 1985; Capponi et al., 1988; Suárez et al., 2002) . One consequence of calcium mobilization is transcription of immediate early genes, including cFos (Clark et al., 1992; Templeton et al., 1998; Jomphe et al., 2003; Daniels et al., 2005; Zhang et al., 2012) . Central administration of AngII activates cFos expression in several brain regions, including the OVLT, SFO, PVN, and SON (Blackburn et al., 1992a; Herbert et al., 1992; , as replicated here. In agreement with previous work (Blackburn et al., 1992a) , DOC pretreatment diminished AngII-induced cFos in the PVN and oxytocin neurosecretion. The novel finding that DOC pretreatment increases cFos expression in the OVLT represents a striking parallel with the behavioral effects of DOC and AngII on sodium ingestion. The OVLT is included in the region referred to as the anteroventral third ventricle, and partial damage to this region disinhibits sodium appetite (Andersson et al., 1975; Fitts et al., 1990; Fitts, 1991) . IP3 receptor activation was necessary for the DOC and AngII cooperativity on sodium intake, without affecting the sodium ingestion stimulated by either hormone alone.
These three findings may be considered together: (1) the IP3 signaling pathway is uniquely necessary for the DOC and AngII cooperative effect on sodium appetite; (2) its downstream effector in the OVLT, cFos, is highest with combined DOC and AngII treatment, unlike cFos labeling in the other brain regions studied; and (3) PVN activity and oxytocin release are suppressed during the cooperative stimulation of sodium appetite. A parsimonious explanation of these results, partially supported by previous studies, would be that DOC treatment inhibits oxytocin neurons in the PVN, which in turn relieves inhibition on a subset of OVLT neurons, which then augments the drive for sodium ingestion based on IP3 signaling. The role of oxytocin in sodium appetite A model has been proposed in which centrally acting AngII simultaneously stimulates and inhibits sodium appetite, with the inhibition caused by oxytocin release in the brain (Stricker and Verbalis, 1987, 1996; Blackburn et al., 1992a) . Other investigators also have observed a disinhibition of sodium appetite after central administration of an oxytocin antagonist or in knock-out mice (Chow et al., 1997; Puryear et al., 2001; Fitts et al., 2003) , although the enhancement of the sodium appetite by an oxytocin antagonist may be somewhat dependent on the dose of AngII (Fitts et al., 2003; Stricker and Verbalis, 2004) . The present results replicate several key findings, including the dampening of AngIIinduced cFos activation of the PVN and oxytocin release by DOC pretreatment. However, the site of oxytocin action to inhibit sodium appetite had been unknown.
The discovery that DOC treatment uniquely enhanced the effect of AngII on cFos expression in the OVLT suggests that it is the target of the oxytocinergic inhibition of sodium appetite. Indeed, oxytocin receptor mRNA is localized to the OVLT (Yoshimura et al., 1993) . Here, we have demonstrated oxytocin fibers disbursed throughout the dorsal cap of the OVLT. The OVLT includes osmosensitive neurons and is thought to function as the brain's primary osmostat (Denton et al., 1996; Johnson et al., 1996) . Many neurons in the OVLT are excited by hypertonicity and inhibited by hypotonicity (Sayer et al., 1984; Honda et al., 1990; Vivas et al., 1990; Nissen et al., 1993) , mediated by members of the transient receptor potential vanilloid proteins (Ciura and Bourque, 2006) . The OVLT sends both GABAergic and glutamatergic projections to a variety of brain regions (Camacho and Phillips, 1981; Richard and Bourque, 1996) , although the functions of these projections remain ill-defined. The present results build on this body of work by correlating the suppression of PVN activity, by either DOC or lidocaine, with increased activation in OVLT neurons. Given that the natriorexic effect of PVN inhibition was reversed with central oxytocin administration, oxytocin is likely the critical inhibitory signal arising from the PVN. Thus, the OVLT, a key sensor of body fluid parameters may also be the target of oxytocin modulation of sodium appetite.
It has been proposed that central oxytocin actions are based on bulk transmission, such as dendritic release in the PVN (Ludwig et al., 2002) . Although this mechanism may apply to some situations, oxytocinergic synaptic contacts have been demonstrated in the ventromedial hypothalamus (Griffin et al., 2010) . Despite its close proximity to ventricular space, the OVLT has a generous supply of varicose axons containing oxytocin, suggesting local release. Tract tracing studies will be valuable to identify the specific population of oxytocin neurons that directly innervate the OVLT.
Our results suggest that oxytocin neurons, rather than autonomic or vasopressin neurons, explain the changes of sodium appetite after PVN-lidocaine administration. Although lidocaine administered into the PVN could potentially reduce blood pressure via reduced sympathetic activity and vasopressin release, hypotension is an unlikely cause of the PVN-lidocaine-induced sodium appetite. In particular, hypotension would also stimulate water intake, which did not occur.
Interpretational limitations
The present work focused on the OVLT, SFO, PVN, and SON, based on previous studies. Brainstem, limbic, gustatory, and other hypothalamic regions are certainly involved, but their contributions were beyond the scope of this study. Likewise, the analysis of cFos expression and the pharmacological disruption of neural activity do not fully address the cascade of information processing within the broader neural network. Given that many hypothalamic areas are reciprocally connected, further studies will be needed to disambiguate the roles that these brain regions play in promoting and inhibiting sodium appetite.
Conclusions
These results rule out the ERK1/2 signaling pathway as an underlying mechanism for DOC-AngII enhancement of sodium appetite. Instead, IP3 signaling is required for the cooperativity of DOC and AngII. Activity in the OVLT and PVN are inversely related, suggesting an inhibitory signal from the PVN to the OVLT. Oxytocin fibers woven throughout the dorsal cap of the OVLT suggest a direct, inhibitory oxytocin input to the OVLT.
